Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Monday, November 2, 2026

⚡ Executive Takeaway

The window's story end just failed its first stress test. Two weeks ago City Therapeutics could debut 24.4 percent above its offer into a falling tape on an RNAi narrative alone. On Friday, with the S&P down 1.8 percent, Aspen Neuroscience and Bambusa finished their first sessions below their offers. The delivery end cleared at full price the same day: Regeneron added 13.3 percent for a quarter without an asterisk, AstraZeneca 7 percent for a reconfirmed year, while Illumina raised its guidance and still lost nearly a fifth of its value because the revenue line is what the market now audits.

That is one market applying one rule: promises no longer carry a premium, delivered numbers do. The two ended market we have tracked since mid October is down to one end. This week grades the rule three ways: Inovio's approval meets a 60 cent stock on Monday, Amgen reports Tuesday after the close, and Summit's discount rides toward November 14.

🧬 A DNA Medicine Gets Its First Approval

The FDA cleared Inovio's Voceryq on Friday evening to cut the surgery cycle in recurrent respiratory papillomatosis, and the company calls it the first approved DNA medicine. INO | PGEN

💰 Friday Paid for Delivered Quarters

Regeneron rose 13.3 percent on a 36 percent revenue quarter, AstraZeneca 7 percent on a beat and a reconfirmed year, and AbbVie raised its guidance and its dividend in the same release. REGN | ABBV | AZN

AbbVie grew revenue 10.3 percent to $17.4 billion on Skyrizi up 22.7 percent and Rinvoq up 23.9 percent, raised full year adjusted EPS to $13.95 to $13.99, lifted the dividend 5.2 percent, and disclosed a completed Apogee acquisition, an approved Parkinson's drug in Juvmo, and an amylin analog moving to Phase 2. Regeneron grew revenue 36 percent to $5.1 billion with non GAAP EPS up 70 percent, expanded its Sanofi alliance for $1.0 billion upfront plus up to $7.0 billion in milestones, and said it expects an FDA decision on cemdisiran in generalized myasthenia gravis next month. AstraZeneca grew 7 percent to $16.2 billion, beat on core EPS and reconfirmed its year, with oncology now 47 percent of revenue. Friday's closes, our arithmetic from settled prices: AbbVie +1.4 percent, Regeneron +13.3 percent, AstraZeneca ADRs +7.0 percent.

🔬 Illumina Raised Its Year and Lost a Fifth of Its Value

The tools and medtech verdicts ran the other way: a beat and raise was worth minus 18.6 percent at Illumina, and a trimmed outlook cost Stryker 6.4 percent. ILMN | SYK | GILD

Illumina's Thursday evening print beat on EPS and raised full year revenue and EPS guidance, but organic growth was 4.8 percent and the quarter carried a $79 million tariff refund benefit; the stock fell 18.6 percent in Friday's first reaction session. Stryker grew 7.7 percent organically yet set a new full year organic range of 6.5 to 7.0 percent that trade coverage read as a cut, with hips down 1.0 percent and $293 million of impairments; it fell 6.4 percent, and its chief executive said the quarter fell short of expectations. Gilead's raised year cleared higher, up 3.1 percent in its own first reaction, while Penumbra, guidance suspended under the pending Boston Scientific deal, slipped 0.9 percent.

🩺 TCT Put the CT Scan on Equal Footing

CT guided stent planning matched invasive ultrasound guidance in a randomized trial published in the New England Journal of Medicine, with procedures 17 minutes shorter. HTFL | ABT | JNJ

Heartflow's P4 trial randomized 1,105 stable coronary disease patients between CT based procedure planning and intravascular ultrasound guidance: 12 month target vessel failure was 4.1 versus 4.6 percent, meeting noninferiority, with median procedure time of 46 versus 63 minutes and less contrast. The vintage caveat: P4 used an earlier version of the planning software, and the separate NAVIGATE-PCI registry's claim that the newer PCI Navigator changed roughly 70 percent of treatment plans is an uncontrolled plan change rate, not an outcome. Abbott's TECTONIC study put its investigational SonicForce coronary lithotripsy system at 0.3 percent target lesion failure and 97 percent procedural success in 335 patients, with no filing timing named.

Johnson & Johnson answered CHIP-BCIS3, the randomized trial that went against Impella, with three observational analyses covering 1,379 patients, including in hospital mortality of 4.7 percent in a PROTECT III subgroup built to match that trial's entry criteria, against the roughly 8 percent it cites from the trial itself. Registry data against a randomized result settles nothing; the randomized PROTECT IV, anticipated in 2027 per the company, will. Anteris reported DurAVR valve outcomes from its EMBARK study, and GE HealthCare launched the Allia Celeo interventional imaging system, a heavy medtech Sunday from San Diego.

📈 Both IPO Debuts Broke Their Offers

Friday produced the window's first broken debuts: Aspen Neuroscience closed 0.7 percent below its offer and Bambusa 6.3 percent below, our arithmetic, on a 1.8 percent S&P down day. ASPE | BBTX

Aspen Neuroscience, the iPSC Parkinson's cell therapy developer, closed its first session at $14.89 against a $15.00 offer that raised about $140.6 million gross; Bambusa Therapeutics, long acting bispecifics, closed at $14.99 against an upsized $16.00 offer worth about $168.9 million. Two weeks ago City Therapeutics debuted 24.4 percent above its offer into a comparable selloff; the premium for paper that cannot yet disappoint has stopped printing. Both closings are expected today, and the 424B4 filings will show whether the underwriters' options were exercised.

🧪 The Genome Editing Draft Gets Its Docket

The FDA's individualized genome editing draft now has a docket number and a comment clock, and savolitinib's filings crossed two more borders on the SAFFRON survival data. HCM | AZN

The Federal Register notice for the individualized human genome editing draft published October 28 under docket FDA-2026-D-11783, with comments due 30 days after publication, late November by our arithmetic. Over the weekend, the EMA validated and Japan's health ministry accepted AstraZeneca's filings for Orpathys plus Tagrisso in MET driven, EGFR mutated lung cancer after progression on an EGFR inhibitor, built on HUTCHMED's Phase 3 SAFFRON trial, where the combination cut the risk of death 32 percent with median overall survival of 17.8 versus 12.9 months. The US application has been under FDA review since September.

📋 Quick Hits

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

📋 The Week in Review